Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis.

Autor: Sobral-Leite M; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. m.leite@nki.nl.; Programa de Farmacologia, Instituto Nacional do Câncer (INCA), Rio de Janeiro, RJ, Brazil. m.leite@nki.nl., Wesseling J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. j.wesseling@nki.nl.; Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. j.wesseling@nki.nl., Smit VT; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. V.T.H.B.M.Smit@lumc.nl., Nevanlinna H; University of Helsinki, Helsinki, Finland. Heli.Nevanlinna@hus.fi.; Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland. Heli.Nevanlinna@hus.fi., van Miltenburg MH; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. m.v.miltenburg@nki.nl., Sanders J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. jo.sanders@nki.nl., Hofland I; Core Facility Molecular Pathology and Biobanking, Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. i.hofland@nki.nl., Blows FM; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. fmb28@medschl.cam.ac.uk., Coulson P; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK. Penny.Coulson@icr.ac.uk., Patrycja G; Breakthrough Breast Cancer Centre, London, UK. patrycja.gazinska@kcl.ac.uk., Schellens JH; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. j.schellens@nki.nl.; Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands. j.schellens@nki.nl., Fagerholm R; University of Helsinki, Helsinki, Finland. rainer.fagerholm@helsinki.fi.; Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland. rainer.fagerholm@helsinki.fi., Heikkilä P; University of Helsinki, Helsinki, Finland. paivi.heikkila@hus.fi.; Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland. paivi.heikkila@hus.fi., Aittomäki K; University of Helsinki, Helsinki, Finland. kristiina.aittomaki@helsinki.fi.; Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland. kristiina.aittomaki@helsinki.fi., Blomqvist C; University of Helsinki, Helsinki, Finland. carl.blomqvist@helsinki.fi.; Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland. carl.blomqvist@helsinki.fi., Provenzano E; Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge, UK. elena.provenzano@addenbrookes.nhs.uk.; Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK. elena.provenzano@addenbrookes.nhs.uk., Ali HR; Cancer Research UK Cambridge Institute Oncology, University of Cambridge, Cambridge, UK. Raza.Ali@cruk.cam.ac.uk.; Department of Pathology, University of Cambridge, Cambridge, UK. Raza.Ali@cruk.cam.ac.uk., Figueroa J; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. figueroaj@mail.nih.gov., Sherman M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. shermanm@exchange.nih.gov.; Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA. shermanm@exchange.nih.gov., Lissowska J; Department of Cancer Epidemiology and Prevention, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. lissowsj@coi.waw.pl., Mannermaa A; School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland. arto.mannermaa@uef.fi.; Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland. arto.mannermaa@uef.fi.; Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland. arto.mannermaa@uef.fi., Kataja V; Cancer Center, Kuopio University Hospital, Kuopio, Finland. vesa.kataja@ksshp.fi.; Jyväskylä Central Hospital, Jyväskylä, Finland. vesa.kataja@ksshp.fi., Kosma VM; School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland. veli-matti.kosma@uef.fi.; Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland. veli-matti.kosma@uef.fi.; Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland. veli-matti.kosma@uef.fi., Hartikainen JM; School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland. jaana.hartikainen@uef.fi.; Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland. jaana.hartikainen@uef.fi.; Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland. jaana.hartikainen@uef.fi., Phillips KA; Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia. Kelly.Phillips@petermac.org.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia. Kelly.Phillips@petermac.org.; Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, The University of Melbourne, Melbourne, Australia. Kelly.Phillips@petermac.org.; Department of Medicine, St Vincent's Hospital, The University of Melbourne, Melbourne, Australia. Kelly.Phillips@petermac.org., Couch FJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. couch.fergus@mayo.edu., Olson JE; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. olsonj@mayo.edu., Vachon C; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. vachon.celine@mayo.edu., Visscher D; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. visscher.daniel@mayo.edu., Brenner H; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. h.brenner@dkfz.de.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. h.brenner@dkfz.de.; Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. h.brenner@dkfz.de., Butterbach K; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. k.butterbach@dkfz.de., Arndt V; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. v.arndt@dkfz.de., Holleczek B; Saarland Cancer Registry, Saarbrücken, Germany. B.Holleczek@gbe-ekr.saarland.de., Hooning MJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. m.hooning@erasmusmc.nl., Hollestelle A; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. a.hollestelle@erasmusmc.nl., Martens JW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. j.martens@erasmusmc.nl., van Deurzen CH; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. c.h.m.vandeurzen@erasmusmc.nl., van de Water B; Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. b.water@lacdr.leidenuniv.nl., Broeks A; Core Facility Molecular Pathology and Biobanking, Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. a.broeks@nki.nl., Chang-Claude J; Division of Cancer Epidemiology, Unit of Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. j.chang-claude@dkfz-heidelberg.de., Chenevix-Trench G; Department of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Georgia.Trench@qimrberghofer.edu.au., Easton DF; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. dfe20@medschl.cam.ac.uk., Pharoah PD; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. paul.pharoah@srl.cam.ac.uk., García-Closas M; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK. Montse.GarciaClosas@icr.ac.uk.; Breakthrough Breast Cancer Centre, London, UK. Montse.GarciaClosas@icr.ac.uk., de Graauw M; Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. m.de.graauw@lacdr.leidenuniv.nl., Schmidt MK; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. mk.schmidt@nki.nl.; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. mk.schmidt@nki.nl.
Jazyk: angličtina
Zdroj: BMC medicine [BMC Med] 2015 Jul 02; Vol. 13, pp. 156. Date of Electronic Publication: 2015 Jul 02.
DOI: 10.1186/s12916-015-0392-6
Abstrakt: Background: Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of this study is to evaluate the association between ANXA1 expression, BRCA1/2 germline carriership, specific tumor subtypes and survival in breast cancer patients.
Methods: Clinical-pathological information and follow-up data were collected from nine breast cancer studies from the Breast Cancer Association Consortium (BCAC) (n = 5,752) and from one study of familial breast cancer patients with BRCA1/2 mutations (n = 107). ANXA1 expression was scored based on the percentage of immunohistochemical staining in tumor cells. Survival analyses were performed using a multivariable Cox model.
Results: The frequency of ANXA1 positive tumors was higher in familial breast cancer patients with BRCA1/2 mutations than in BCAC patients, with 48.6 % versus 12.4 %, respectively; P <0.0001. ANXA1 was also highly expressed in BCAC tumors that were poorly differentiated, triple negative, EGFR-CK5/6 positive or had developed in patients at a young age. In the first 5 years of follow-up, patients with ANXA1 positive tumors had a worse breast cancer-specific survival (BCSS) than ANXA1 negative (HRadj = 1.35; 95 % CI = 1.05-1.73), but the association weakened after 10 years (HRadj = 1.13; 95 % CI = 0.91-1.40). ANXA1 was a significant independent predictor of survival in HER2+ patients (10-years BCSS: HRadj = 1.70; 95 % CI = 1.17-2.45).
Conclusions: ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and correlated with poor prognosis features: triple negative and poorly differentiated tumors. ANXA1 might be a biomarker candidate for breast cancer survival prediction in high risk groups such as HER2+ cases.
Databáze: MEDLINE
Externí odkaz: